Recurrence in Resected Gastroenteropancreatic Neuroendocrine Tumors

JAMA Oncol. 2018 Apr 1;4(4):583-585. doi: 10.1001/jamaoncol.2018.0024.

Authors

Simron Singh¹, David L Chan¹, Lesley Moody², Ning Liu³, Hadas D Fischer³, Peter C Austin^{2

3}, Eva Segelov⁴

Affiliations

¹ Division of Medical Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
² Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada.
³ Institute for Evaluative Clinical Sciences, Toronto, Ontario, Canada.
⁴ Department of Oncology, Monash Health and Monash University, Melbourne, Australia.

Abstract

This cohort study examines recurrence outcomes in patients with fully resected gastroenteropancreatic neuroendocrine tumors.

Publication types

Letter

MeSH terms

Aged
Cohort Studies
Digestive System Surgical Procedures
Female
Follow-Up Studies
Gastrointestinal Neoplasms / mortality
Gastrointestinal Neoplasms / pathology
Gastrointestinal Neoplasms / surgery
Humans
Incidence
Intestinal Neoplasms / epidemiology*
Intestinal Neoplasms / pathology*
Intestinal Neoplasms / surgery
Male
Middle Aged
Neoplasm Recurrence, Local / epidemiology*
Neoplasm Recurrence, Local / pathology
Neoplasm Recurrence, Local / surgery
Neoplasm, Residual
Neuroendocrine Tumors / epidemiology*
Neuroendocrine Tumors / pathology*
Neuroendocrine Tumors / surgery
Ontario / epidemiology
Pancreatic Neoplasms / epidemiology*
Pancreatic Neoplasms / pathology*
Pancreatic Neoplasms / surgery
Recurrence
Stomach Neoplasms / epidemiology*
Stomach Neoplasms / pathology*
Stomach Neoplasms / surgery
Survival Analysis

Supplementary concepts

Gastro-enteropancreatic neuroendocrine tumor